Novavax Executive and Leadership Team

John Jacobs, the President, Chief Executive Officer & Member of The Board of Directors at Novavax, directs the overarching corporate strategy and long-term vision for the biotechnology firm. Jacobs manages the alignment of research initiatives with commercial objectives, ensuring the successful deployment of vaccine candidates across global markets. By fostering strategic partnerships with major pharmaceutical entities, the President, Chief Executive Officer & Member of The Board of Directors secures the necessary resources to scale production and distribution. This leadership role involves constant engagement with the Board to optimize operational efficiency and drive shareholder value. Through rigorous oversight of the company's recombinant protein platform, John Jacobs maintains a focus on addressing critical infectious disease threats. Ultimately, the executive ensures that the organization remains at the forefront of medical innovation while navigating complex regulatory landscapes and expanding the reach of life-saving vaccine technologies.

Ian Watkins, the Executive Vice President & Chief Human Resources Officer at Novavax, architects the organizational culture and talent acquisition strategies necessary to support complex biotechnology operations. Watkins oversees the development of high-performance teams capable of executing the company's mission to combat infectious diseases. By implementing robust human capital frameworks, the Executive Vice President & Chief Human Resources Officer ensures that the workforce remains aligned with the evolving needs of the vaccine pipeline. This leadership role involves managing global talent initiatives that span diverse operational regions, fostering an environment of innovation and scientific excellence. Through strategic workforce planning, Ian Watkins directly impacts the company's ability to attract top-tier researchers and operational experts. Ultimately, the executive drives the internal structural growth required to sustain long-term success in the competitive pharmaceutical sector while maintaining a focus on employee engagement and organizational agility.

Louis Fries, the Chief Medical Officer at Novavax, directs the clinical evaluation and medical safety protocols for the entire vaccine portfolio. Fries oversees the rigorous testing of candidates targeting respiratory syncytial virus, influenza, and other pathogens, ensuring adherence to the highest standards of scientific integrity. By collaborating with regulatory bodies and internal research teams, the Chief Medical Officer validates the efficacy of the company's proprietary nanoparticle technology. This leadership role involves interpreting complex clinical data to guide the development of vaccines that address urgent global health needs. Through the management of medical affairs, Louis Fries ensures that all clinical programs align with the broader mission of protecting populations against serious infectious diseases. Ultimately, the executive provides the medical expertise required to navigate the transition from laboratory discovery to commercialization, securing the safety and reliability of every product within the pipeline.

Mark Casey, the Executive Vice President & Chief Legal Officer at Novavax, architects the legal framework governing intellectual property, licensing agreements, and global compliance. Casey oversees the protection of the company's proprietary adjuvant platform and recombinant protein technology, ensuring that all innovations remain secure within the competitive biotechnology landscape. By managing complex collaborations with global pharmaceutical partners, the Executive Vice President & Chief Legal Officer mitigates risk and facilitates the expansion of the vaccine pipeline. This leadership role involves navigating international regulatory requirements to support the commercialization of products across diverse markets. Through the oversight of corporate governance and legal strategy, Mark Casey ensures that the organization operates with transparency and adherence to industry standards. Ultimately, the executive secures the legal foundation necessary for the company to continue its mission of developing and delivering essential vaccines to combat infectious diseases on a global scale.

Raburn Mallory, the Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer at Novavax, directs the execution of clinical trials and the advancement of the vaccine pipeline. Mallory oversees the operational design of studies targeting malaria, shingles, and other infectious diseases, ensuring that research objectives meet critical milestones. By coordinating with the Chief Medical Officer, the Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer translates scientific concepts into actionable clinical programs. This leadership role involves managing the logistics of large-scale trials across various geographic regions to demonstrate the efficacy of the company's nanoparticle technology. Through the optimization of clinical development processes, Raburn Mallory accelerates the path from research to regulatory approval. Ultimately, the executive ensures that the company's vaccine candidates undergo thorough evaluation, providing the necessary evidence to support the commercialization of life-saving medical solutions.